Hutchison China MediTech (NASDAQ:HCM) has held its pre-New Drug Application (NDA) meeting with the FDA for surufatinib for the treatment of patients with advanced neuroendocrine tumors.
Chi-Med has initiated preparatory work for the
U.S. NDA and intends to utilize a rolling submission under Fast Track
Designation Status.
The planned start of the NDA submission is late 2020.
https://seekingalpha.com/news/3578884-chi-med-to-submit-surufatinib-nda-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.